|
|
|
Innate Pharma Sa (NASDAQ: IPHA) |
|
IPHA's Market share relative to its competitors, as of Q4 2023
As of Q4 2023 (Revenue in Millions of $)
Date modified: 2025-06-23T23:46:18+00:00
|
Select the Relationship:
|
|
Select the Category:
|
|
| COMPANY NAME |
REVENUES
12 Months Ending
Q4 2023 |
MARKET SHARE
12 Months
Q4 2023 |
MARKET SHARE
MRQ
Q4 2023 |
MARKET SHARE
A Quarter Before
Q3 2023 |
| Innate Pharma Sa |
69.04 |
0.03% |
0.03 % |
0.00 % |
| Merck and Co Inc |
63,922.00 |
25.34% |
25.05% |
24.70% |
| Bristol myers Squibb Company |
47,636.00 |
18.88% |
18.07% |
19.51% |
| Astrazeneca Plc |
45,811.00 |
18.16% |
18.16% |
0.00% |
| Amgen Inc |
33,424.00 |
13.25% |
14.65% |
13.44% |
| Gilead Sciences Inc |
28,735.00 |
11.39% |
10.75% |
11.96% |
| Regeneron Pharmaceuticals Inc |
14,085.70 |
5.58% |
4.88% |
5.99% |
| Biogen Inc |
9,816.40 |
3.89% |
3.92% |
3.88% |
| Seagen Inc |
2,300.35 |
0.91% |
1.05% |
0.95% |
| Exelixis Inc |
2,298.92 |
0.91% |
0.90% |
0.90% |
| Novavax inc |
1,254.96 |
0.50% |
1.08% |
0.14% |
| Halozyme Therapeutics Inc |
1,084.31 |
0.43% |
0.43% |
0.47% |
| Argenx se |
856.01 |
0.34% |
0.34% |
0.00% |
| Iovance Biotherapeutics inc |
212.68 |
0.08% |
0.08% |
0.12% |
| Coherus Biosciences inc |
197.50 |
0.08% |
0.01% |
0.09% |
| Alector Inc |
88.34 |
0.04% |
0.01% |
0.09% |
| Sutro Biopharma Inc |
66.43 |
0.03% |
0.03% |
0.02% |
| Recursion Pharmaceuticals Inc |
59.79 |
0.02% |
0.02% |
0.01% |
| Kymera Therapeutics Inc |
58.89 |
0.02% |
0.04% |
0.01% |
| Sab Biotherapeutics Inc |
58.72 |
0.02% |
0.00% |
0.00% |
| Sorrento Therapeutics Inc |
51.02 |
0.02% |
0.02% |
0.03% |
| Scholar Rock Holding Corp |
47.30 |
0.02% |
0.00% |
0.00% |
| Invivyd Inc |
36.69 |
0.01% |
0.02% |
0.02% |
| Immunitybio inc |
31.22 |
0.01% |
0.03% |
0.01% |
| Revolution Medicines Inc |
29.51 |
0.01% |
0.00% |
0.00% |
| Vir Biotechnology Inc |
20.86 |
0.01% |
0.00% |
0.02% |
| Ambrx Biopharma Inc |
8.60 |
0.00% |
0.00% |
0.00% |
| Omega Therapeutics Inc |
8.09 |
0.00% |
0.00% |
0.00% |
| Molecular Partners Ag |
7.04 |
0.00% |
0.00% |
0.00% |
| Mesoblast Ltd |
5.90 |
0.00% |
0.00% |
0.00% |
| Inhibrx Biosciences Inc |
4.77 |
0.00% |
0.00% |
0.00% |
| Armata Pharmaceuticals Inc |
4.53 |
0.00% |
0.00% |
0.00% |
| Dbv Technologies S a |
4.39 |
0.00% |
0.00% |
0.00% |
| Dyadic International Inc |
3.55 |
0.00% |
0.00% |
0.00% |
| Enzon Pharmaceuticals inc |
1.72 |
0.00% |
0.00% |
0.00% |
| Fusion Pharmaceuticals Inc |
0.90 |
0.00% |
0.00% |
0.00% |
| Inmune Bio Inc |
0.36 |
0.00% |
0.00% |
0.00% |
| Opthea Limited |
0.12 |
0.00% |
0.00% |
0.00% |
| Candel Therapeutics Inc |
0.03 |
0.00% |
0.00% |
0.00% |
| Aceragen Inc |
0.00 |
0.00% |
0.00% |
0.01% |
| Apogee Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Black Diamond Therapeutics Inc |
0.00 |
0.00% |
0.11% |
0.00% |
| Cullinan Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Channel Therapeutics Corporation |
0.00 |
0.00% |
0.00% |
0.00% |
| Calidi Biotherapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Compass Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Cardiol Therapeutics inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Entera Bio Ltd |
0.00 |
0.00% |
0.00% |
0.00% |
| Jasper Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Kodiak Sciences Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Ladrx Corporation |
0.00 |
0.00% |
0.00% |
0.00% |
| Lexeo Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Nkgen Biotech Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Palisade Bio Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Phoenix Biotech Acquisition Corp |
0.00 |
0.00% |
0.00% |
0.00% |
| Biomx Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Peak Bio Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Prokidney Corp |
0.00 |
0.00% |
0.00% |
0.00% |
| Mosaic Immunoengineering Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Quince Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Scinai Immunotherapeutics Ltd |
0.00 |
0.00% |
0.00% |
0.00% |
| Turnstone Biologics Corp |
0.00 |
0.00% |
0.00% |
0.00% |
| Tevogen Bio Holdings Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Zura Bio Limited |
0.00 |
0.00% |
0.00% |
0.00% |
| SUBTOTAL |
252,302.66 |
100% |
62,003.41 |
100% |
IPHA's Market share relative to its competitors, as of Q4 2023 within the Biotechnology & Pharmaceuticals Industry
As of Q4 2023
IPHA's Market share relative to its competitors, as of Q4 2023 within the Healthcare Sector
As of Q4 2023
Note: Market share is calculated based on total revenue. To get a more accurate picture of Innate Pharma Sa's market divisions, geographic dispersion, segments, products, and services, visit Innate Pharma Sa's Business Segment. The list includes publicly traded companies only. More information about the sources of this report can be found here. |
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
